<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00420654</url>
  </required_header>
  <id_info>
    <org_study_id>2005-BH-GH</org_study_id>
    <nct_id>NCT00420654</nct_id>
  </id_info>
  <brief_title>Growth Hormone Treatment of Women With Turner Syndrome</brief_title>
  <official_title>Growth Hormone Treatment of Women With Turner Syndrome: Body Composition and Heart Function.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Britta E. Hjerrild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Growth hormone treatment is used in girls with Turner syndrome to increase final height. The
      aim of this study is to evaluate the effect of growth hormone treatment on body composition
      and heart function in adult women with Turner syndrome. The hypothesis is that the fat mass
      will decrease and lean body mass will increase. There is only very limited documentation of
      the effect on the heart in this study population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomised, double-blinded, controlled clinical trial to evaluate the effect
      of growth hormone (GH) treatment on adult women with Turner syndrome. The endpoints will be
      changes in body composition and heart function evaluated by echocardiography (ECHO) and
      positron emission tomography (PET).

      Phase one: 6 months of GH or placebo treatment. Phase two: &quot;open label&quot; all participants are
      treated with GH for 12 months. At baseline, healthy controls will be examined, but will not
      receive any treatment
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body composition: fat mass and lean body mass</measure>
    <time_frame>6 months + 18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Myocardial perfusion and glucose uptake, evaluated by positron emission tomography</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart function evaluated by echocardiography (conventional and tissue doppler)</measure>
    <time_frame>6 months + 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profile</measure>
    <time_frame>6 months + 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour ambulatory blood pressure</measure>
    <time_frame>6 months + 18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Turner Syndrome</condition>
  <arm_group>
    <arm_group_label>A1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>A2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>A3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Growth Hormone</intervention_name>
    <description>1.25 mg, 6 months</description>
    <arm_group_label>A1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Equivalent to 1.25 mg, 6 months</description>
    <arm_group_label>A2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Healthy controls</intervention_name>
    <description>Healthy controls</description>
    <arm_group_label>A3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Turner syndrome

          -  Age 20-40

        Exclusion Criteria:

          -  Symptomatic heart disease

          -  Anti hypertensive treatment

          -  Untreated thyroid disease

          -  Adipositas (BMI &gt; 35)

          -  Treatment with glucocorticoids

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens S. Christiansen, prof. dr.med</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Aarhus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Department M (Endocrinology and Diabetes), Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <state>DK</state>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2007</study_first_submitted>
  <study_first_submitted_qc>January 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2007</study_first_posted>
  <last_update_submitted>November 6, 2011</last_update_submitted>
  <last_update_submitted_qc>November 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Aarhus</investigator_affiliation>
    <investigator_full_name>Britta E. Hjerrild</investigator_full_name>
    <investigator_title>MD PhD Clinical assistent</investigator_title>
  </responsible_party>
  <keyword>Turner syndrome</keyword>
  <keyword>growth hormone treatment</keyword>
  <keyword>positron emission tomography</keyword>
  <keyword>heart</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Turner Syndrome</mesh_term>
    <mesh_term>Gonadal Dysgenesis</mesh_term>
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

